FDA AI Action Plan Explained
A Lifecycle Blueprint for Regulating Adaptive Medical AI
The FDA Artificial Intelligence Action Plan outlines the agency’s lifecycle-oriented approach to overseeing AI and machine learning–based medical software in the United States. Specifically, it responds to the limitations of traditional regulatory models when applied to adaptive systems and reflects modern software development and real-world clinical deployment.
Importantly, the Action Plan builds on existing digital health programs and sets the FDA’s policy direction for how AI-based medical devices may be developed, validated, and maintained over time, with detailed requirements addressed in subsequent guidance. Notably, it is intended for organizations operating in regulated environments, rather than for early-stage or experimental development.
Regulatory Context and Policy Foundation
Evolution of FDA Oversight for Software-Based Devices
Historically, the FDA regulated software through frameworks designed for static functionality. Early SaMD regulatory guidance assumed fixed logic and predictable behavior. However, this approach became insufficient as machine learning models began adapting based on new data inputs and real-world usage patterns.
As a result, the emergence of continuously learning systems created regulatory gaps related to performance drift, retraining, and validation continuity. Consequently, these gaps prompted the FDA to reevaluate how oversight could remain rigorous while still allowing responsible iteration within deployed systems.
Relationship to Prior FDA Initiatives
Importantly, the AI Action Plan builds directly on earlier FDA AI guidance for medical device development. That document introduced core concepts such as predetermined change control and lifecycle-based oversight, which received extensive industry feedback during public consultation.
In other words, the Action Plan reflects refinement rather than replacement. Furthermore, it incorporates lessons learned from the Software Precertification Pilot and aligns with broader digital health policy goals focused on risk-based regulation and evidence-driven review.
Structural Overview of the FDA AI Action Plan
Core Objectives of the Action Plan
Overall, the Action Plan establishes a unified approach for regulating AI-enabled medical software across development, deployment, and postmarket phases. At the same time, it emphasizes accountability without restricting technical innovation or unnecessarily slowing iteration cycles.
To that end, the FDA structured the plan around five interdependent focus areas that collectively define expectations for development rigor, transparency, performance assurance, and lifecycle management.
Relationship to Existing Regulatory Pathways
Importantly, the Action Plan does not replace existing regulatory pathways, such as:
Instead, it introduces mechanisms that operate within these established frameworks to accommodate the adaptive behavior of AI-enabled software.
Accordingly, developers are expected to embed AI-specific documentation and controls into their current submission processes. In practice, there is no need to pursue separate regulatory tracks; rather, integration should occur within the established regulatory pathways.
Tailored Regulatory Framework for AI and ML Based SaMD
Predetermined Change Control and Lifecycle Oversight
A foundational element of the Action Plan is the concept of predefined change control. This enables developers to implement certain algorithm modifications without submitting a new application, provided those changes remain within approved boundaries.
Key components include:
- SaMD Pre-Specifications defining anticipated modifications
- Algorithm Change Protocols describing validation methods
- Documentation of safeguards ensuring ongoing safety
This approach supports controlled evolution while maintaining regulatory visibility.
Integration With the Total Product Lifecycle Model
The FDA applies a Total Product Lifecycle (TPLC) approach to AI systems to ensure continuity across development, deployment, and postmarket oversight. Evaluation does not end at initial clearance; instead, it extends throughout the system’s operational use.
FDA has indicated that manufacturers should describe how they manage updates to the AI system, retraining of machine learning models, and ongoing performance monitoring.
All of these activities must be addressed within a lifecycle-based risk management framework that is both auditable and reproducible. This approach supports long-term safety, effectiveness, and regulatory compliance as AI systems evolve over time.
Advancing Good Machine Learning Practice
Purpose and Scope of GMLP
Good Machine Learning Practice (GMLP) defines the technical expectations for developing reliable AI systems within regulated environments. It builds on traditional software validation principles and extends them to include:
- Data management
- Training methodologies
- Model evaluation processes
Rather than relying on prescriptive rulemaking, the FDA promotes GMLP through collaboration with standards bodies and industry stakeholders. This collaborative approach provides the necessary flexibility while maintaining consistent technical rigor across AI development efforts.
Core Technical Components of GMLP
GMLP encompasses multiple development and validation dimensions, including:
- Data provenance and labeling controls
- Training and testing dataset separation
- Model versioning and traceability
- Reproducibility of results across environments
These elements form the technical basis for regulatory confidence in AI-based devices.
Transparency and User Communication
Transparency as a Regulatory Requirement
The FDA considers transparency essential for the safe clinical use of AI-enabled systems. Clinicians must understand:
- What the system does
- How it behaves
- Under what conditions may its performance change
Transparency requirements go beyond basic labeling. They also include supporting documentation that enables informed clinical decision-making and promotes the safe integration of AI into existing workflows. This comprehensive approach helps build trust and ensures appropriate use in real-world healthcare settings.
Implementation Expectations for Manufacturers
Manufacturers are expected to provide clear communication regarding:
- Model intended use and limitations
- Version history and update notifications
- Performance characteristics across use cases
These disclosures support proper clinical interpretation and reduce the risk of misuse or overreliance.
Promoting Robustness and Algorithm Reliability
Evaluation of Performance Stability
Robustness refers to a system’s ability to maintain consistent performance across a wide range of conditions. The FDA expects developers to demonstrate that AI models operate reliably across:
- Different patient populations
- Varying data sources
- Diverse clinical environments
To meet these expectations, validation strategies must go beyond internal datasets. They should reflect the real-world variability that systems are likely to encounter once deployed, ensuring dependable and equitable performance in practice.
Addressing Data and Model Limitations
Developers must clearly document known performance limitations and define appropriate mitigation strategies to address them. This includes:
- Handling edge cases
- Detecting out-of-distribution inputs
- Monitoring performance degradation over time
Performance evaluation must be continuous, not limited to premarket testing. This ongoing assessment reinforces the FDA’s lifecycle-based regulatory approach, ensuring that AI systems remain reliable and safe throughout their operational use.
Real-World Performance Monitoring
Role of Postmarket Surveillance
Postmarket monitoring is a central component of the FDA’s AI oversight strategy. Continuous performance assessment is essential to ensure that deployed models remain safe and effective as clinical conditions and environments evolve.
The FDA encourages the use of real-world data to support:
- Ongoing evaluation
- Early detection of issues
- Timely corrective actions when needed
This approach reinforces the commitment to lifecycle oversight and adaptability in managing AI-enabled systems over time.
Operational Expectations for Monitoring Systems
Effective monitoring programs typically include:
- Automated performance tracking
- Drift detection mechanisms
- Defined thresholds for corrective action
- Integration with quality management systems
These controls allow manufacturers to respond quickly to performance deviations while maintaining regulatory compliance.
Regulatory Submissions and Lifecycle Management
Submission Requirements for AI/ML Devices
When proposing a Predetermined Change Control Plan (PCCP), developers should include artifacts that reflect the adaptive nature of their systems. This includes SaMD Pre-Specifications, Algorithm Change Protocols, and detailed validation reports aligned with predefined modification boundaries.
Submissions must also demonstrate how changes will be tracked, verified, and controlled. The FDA expects a full picture of how learning algorithms will evolve post-clearance.
Lifecycle Documentation and Change Control
Under FDA’s Total Product Lifecycle approach, planned post-deployment changes are expected to remain within reviewed and approved parameters when a PCCP is in place. Manufacturers must implement structured change management, including:
- Defined retraining triggers
- Regression testing plans
- Model version control logs
- Audit trails and rollback processes
These elements are reviewed by the FDA when assessing the safety and effectiveness of AI-enabled devices that incorporate planned algorithm modifications, particularly when a PCCP is proposed as part of the marketing submission.
Operational Impact on Development and Quality Assurance
Alignment with MLOps and DevOps Pipelines
Traditional software development teams are adjusting to include model training and monitoring as core operational activities. Regulatory expectations now require these elements to be versioned, validated, and documented in the same way source code is tracked and reviewed.
Teams must integrate compliance into their development infrastructure, using tooling that links model performance to specific training sets and control logic.
Quality Assurance Across the Model Lifecycle
QA organizations must expand their scope to cover not only software testing but model integrity, bias evaluation, and performance robustness. Internal processes must reflect AI-specific risks and mitigations.
Effective QA programs should include:
- Performance testing on new input distributions
- Drift monitoring and alerting systems
- Documentation of all deployed model versions
- Traceability between training data and released models
These functions ensure inspection readiness and postmarket compliance for adaptive systems.
Cross-Agency and Standards Integration
Federal Coordination and Technical Interoperability
The FDA engages with other government agencies and standards organizations to promote consistency in data standards, quality expectations, and performance evaluation for AI-enabled health technologies. While the AI Action Plan emphasizes collaboration and the use of consensus standards, it does not enumerate all partner agencies.
Such coordination ensures consistency across data standards, quality expectations, and performance metrics relevant to AI-based systems.
Use of Consensus Standards and Guidance Alignment
FDA guidance in this area aligns with commonly used consensus standards and best practices. FDA guidance encourages the use of:
- AAMI/ISO 13485 for quality management
- IEC 62304 for software lifecycle processes
- ISO/IEC TR 24028 for AI system robustness
- NIST guidance on AI risk management and fairness
These standards provide structure to GMLP and lifecycle documentation, enabling manufacturers to work within known regulatory expectations.
Final Thoughts
The FDA AI Action Plan defines a structured, operational approach to regulating AI and machine learning in medical devices. It delivers actionable policy aligned with the needs of regulated software developers and emphasizes lifecycle compliance, transparency, and continuous oversight.
For professional teams working in regulated digital health, the plan offers clarity and technical direction. Success in this environment requires aligning internal development and validation processes with FDA expectations. The goal is not simply approval, but sustained safety and performance across a product’s lifecycle in real-world use.
About Enlil: Powering Regulatory Confidence for AI-Driven MedTech
At Enlil, we understand the complexity of bringing AI-enabled medical devices to market. As the FDA advances initiatives like the AI Action Plan, the demand for compliance automation, lifecycle transparency, and end-to-end traceability is greater than ever for MedTech innovators.
Enlil’s Agentic AI platform was designed to meet this challenge. By unifying PLM, QMS, MES, and ERP in a single cloud-native system, we give MedTech teams the tools to streamline regulatory submissions and ensure audit-ready traceability throughout every stage of product development and commercialization.
Whether you’re an OEM, a contract manufacturer, a product design partner, or a regulatory consultant, Enlil empowers your team with:
- A unified source of truth across product, quality, and regulatory data
- Agentic AI for intelligent automation of submission documentation
- Continuous compliance from concept through commercialization
- Actionable insights to reduce rework and accelerate approvals
As regulatory expectations increase for AI/ML-based SaMD, Enlil helps teams proactively align with frameworks like the FDA’s Total Product Lifecycle approach and GMLP standards. We support every stakeholder in the ecosystem with tools that simplify complexity without compromising compliance.


